Eckert Seamans Cherin & Mellott's proposed $45 million settlement for the benefit of investors defrauded by cash advance company Par Funding may be in danger from an unexpected source: the recent U.S. Supreme Court ruling that blew up the massive bankruptcy deal negotiated by opioid manufacturer Purdue Pharma.